Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.
Researched for: PepTools vendor-neutral scientific reference catalog
Also known as: semaglutide oral tablet, oral semaglutide tablet, semaglutide, Rybelsus
Semaglutide is a modified human GLP-1 analogue with 94% sequence homology to native human GLP-1. It selectively activates the GLP-1 receptor and produces glucose-dependent increases in insulin secretion, reductions in glucagon secretion, and a minor delay in early postprandial gastric emptying. Oral semaglutide is absorbed predominantly in the stomach with the aid of SNAC. U.S. labeling describes two formulations: R1 containing 3 mg, 7 mg, or 14 mg semaglutide per tablet, and R2 containing 1.5 mg, 4 mg, or 9 mg per tablet; the two formulations are not substitutable on a milligram-for-milligram basis.
Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
The FDA-labeled R1 reference regimen is 3 mg orally once daily during days 1 through 30, followed by 7 mg once daily; 14 mg once daily may be used after escalation when additional glycemic control is needed. The FDA-labeled R2 reference regimen is 1.5 mg once daily during days 1 through 30, followed by 4 mg once daily; 9 mg once daily may be used after escalation when additional glycemic control is needed. These are labeled reference regimens, not individualized treatment instructions. Oral absorption is formulation- and administration-condition-dependent; the FDA label specifies administration in the morning on an empty stomach with a limited volume of water and a post-dose fasting interval. Early clinical pharmacology studies used investigational oral semaglutide doses and co-formulated SNAC amounts that should not be interpreted as current labeled strengths.
Supplementary research context only. Not medical advice or a treatment recommendation.
CAS RN 910463-68-2; PubChem CID 56843331; FDA UNII 53AXN4NNHX; molecular formula C187H291N45O59; molecular weight 4113.58 g/mol; ATC A10BJ06
Semaglutide is a white to almost white hygroscopic peptide powder. FDA labeling reports estimated absolute bioavailability of approximately 0.4% to 1% for formulation R1 and 1% to 2% for formulation R2. Maximum plasma concentration is reached approximately 1 hour after oral administration under labeled conditions. R1 tablets contain semaglutide, SNAC, magnesium stearate, microcrystalline cellulose, and povidone; R2 tablets contain semaglutide, SNAC, and magnesium stearate.
Reflects published research. Educational reference — not a recommendation for use.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Published articles on this site that mention Oral semaglutide or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.